logo

Ronald Mitsuyasu, MD

Ronald Mitsuyasu, MD

Oncology Los Angeles, CA

Professor of Medicine, David Geffen School of Medicine at UCLA. Director, UCLA CARE Center

Office Address

Office Map
  • 1399 S. Roxbury Drive
    Suite 100
    Los Angeles, CA 90035
    Phone: (310) 794-9718
    Fax: (310) 557-1899

Dr. Mitsuyasu's Clinical Specialties & Interests

  • Oncology: General Oncology
  • Clinical Interests: Immunology; HIV; Hematology/Oncology; HIV/AIDS/ immunotherapy; gene therapy; general oncology

Dr. Mitsuyasu's Faculty Appointments & Work History

  • Professor of MedicineUniversity of California, Los Angeles
    Los Angeles, CA

Dr. Mitsuyasu's Education & Medical Training

  • UCLA Medical CenterUCLA Medical CenterFellowship, Hematology
  • Rush University Medical CenterRush University Medical CenterResidency, Internal Medicine
  • UCLA Sch of MedDavid Geffen School of Medicine at UCLAMedical School

Dr. Mitsuyasu's Certifications & Licensure

  • CA State Medical LicenseCA State Medical License1981 - 2015
  • American Board of Internal MedicineAmerican Board of Internal MedicineInternal Medicine, 1981

Dr. Mitsuyasu's Awards, Honors, & Recognition

  • SuperDoctors.comSuper DoctorSuperDoctors.com

Dr. Mitsuyasu's Clinical Trials

Dr. Mitsuyasu's Publications & Presentations

PubMed | Citations by Web of Science®

Grant Support

  • South American Prevention Of HIV Research Training Program (SAPHIR)
    South American Prevention Of HIV Research Training Program (SAPHIR)National Institute Of Mental Health
    2011 - 2011
  • Network Core Research LAB
    Network Core Research LABNational Cancer Institute
    2010 - 2011
  • Ucla-Usc Combined LOS Angeles Core Site
    Ucla-Usc Combined LOS Angeles Core SiteNational Cancer Institute
    2010 - 2011
  • AIDS Malignancy Clinical Trials Consortium (AMC)
    AIDS Malignancy Clinical Trials Consortium (AMC)National Cancer Institute
    2010 - 2012
  • AMC Group Chairman, University Of California, LA
    AMC Group Chairman, University Of California, LANational Cancer Institute
    2010 - 2011
  • A Phase II Trial Of Combined Modality Therapy PLUS Cetuximab In Hiv-Associated A
    A Phase II Trial Of Combined Modality Therapy PLUS Cetuximab In Hiv-Associated ANational Center For Research Resources
    2010 - 2010
  • A Phase II Trial Of Doxil, Rituximab, Cyclophosphamide, Vincristine, And Prednis
    A Phase II Trial Of Doxil, Rituximab, Cyclophosphamide, Vincristine, And PrednisNational Center For Research Resources
    2010 - 2010
  • A Prospective Phase II Study Of A High DOSE, Short Course Regimen (R-Codox-M/Iva
    A Prospective Phase II Study Of A High DOSE, Short Course Regimen (R-Codox-M/IvaNational Center For Research Resources
    2010 - 2010
  • A Single Arm, Open-Label Pilot Trial Of The Safety And Immunogenicity Of A Quadr
    A Single Arm, Open-Label Pilot Trial Of The Safety And Immunogenicity Of A QuadrNational Center For Research Resources
    2009 - 2010
  • Phase IIA Trial Of 1% Topical Cidofovir For Treatment Of High-Grade Perianal Squ
    Phase IIA Trial Of 1% Topical Cidofovir For Treatment Of High-Grade Perianal SquNational Center For Research Resources
    2009 - 2010
  • Short Course Regimen (R-Codox-M/Ivac) I
    Short Course Regimen (R-Codox-M/Ivac) INational Center For Research Resources
    2009 - 2009
  • Double-Blind Phase II Study Of Multiple Doses Of Palifermin (RHUKGF) For AIDS
    Double-Blind Phase II Study Of Multiple Doses Of Palifermin (RHUKGF) For AIDSNational Center For Research Resources
    2009 - 2009
  • A Phase II Trial Of Doxil, Rituximab, Cyclophosphamide,
    A Phase II Trial Of Doxil, Rituximab, Cyclophosphamide,National Center For Research Resources
    2009 - 2009
  • A Phase II Trial Of Imatinib Mesylate (GLEEVEC) In Patients With HIV Related
    A Phase II Trial Of Imatinib Mesylate (GLEEVEC) In Patients With HIV RelatedNational Center For Research Resources
    2007 - 2008
  • AMC 036:  A Phase II Trial Of Topical Halofuginone In Patients With HIV Relat
    AMC 036: A Phase II Trial Of Topical Halofuginone In Patients With HIV RelatNational Center For Research Resources
    2006 - 2008
  • AIDS Malignancy Clinical Trials Consortium
    AIDS Malignancy Clinical Trials ConsortiumNational Cancer Institute
    2006 - 2009
  • A Phase II Double-Blind, Randomized, Placebo-Controlled Study To Evaluate The
    A Phase II Double-Blind, Randomized, Placebo-Controlled Study To Evaluate TheNational Center For Research Resources
    2006 - 2008
  • Funding PLAN Additions
    Funding PLAN AdditionsNational Cancer Institute
    2006 - 2006
  • Recruitment And Retention
    Recruitment And RetentionNational Cancer Institute
    2006 - 2006
  • Group Chair Administrative Office &Overview Of Entire Application
    Group Chair Administrative Office &Overview Of Entire ApplicationNational Cancer Institute
    2006 - 2006
  • Discretionary Funding
    Discretionary FundingNational Cancer Institute
    2006 - 2006
  • Improving Immune Reconstruction With Growth Hormone In Hiv-Infected Subjects
    Improving Immune Reconstruction With Growth Hormone In Hiv-Infected SubjectsNational Center For Research Resources
    2005 - 2006
  • Randomized Trial Of Standard Chemotherapy With Or Without The Addition Of Ritux)
    Randomized Trial Of Standard Chemotherapy With Or Without The Addition Of Ritux)National Center For Research Resources
    2005 - 2005
  • A Randomized Phase I/II Pilot Study Of Intermittent Withdrawal Of Antiretrovi
    A Randomized Phase I/II Pilot Study Of Intermittent Withdrawal Of AntiretroviNational Center For Research Resources
    2005 - 2005
  • Exploratory, Open-Label, Randomized Trial To Evaluate
    Exploratory, Open-Label, Randomized Trial To EvaluateNational Center For Research Resources
    2004 - 2004
  • Rituxan For Treatment Of Hiv-Associated Non-Hodgkin'S LY
    Rituxan For Treatment Of Hiv-Associated Non-Hodgkin'S LYNational Center For Research Resources
    2004 - 2004
  • Improving Immune Reconstruction With Growth Hormone In Hiv-Infected Subjects...
    Improving Immune Reconstruction With Growth Hormone In Hiv-Infected Subjects...National Center For Research Resources
    2004 - 2004
  • Aids-Associated Malignancies Clinical Trials Consortium
    Aids-Associated Malignancies Clinical Trials ConsortiumNational Cancer Institute
    2003 - 2005
  • Phase I Trial Of Antitumor Activity Of Inf Alpha
    Phase I Trial Of Antitumor Activity Of Inf AlphaNational Center For Research Resources
    2001 - 2001
  • Comparison Study Of Liposomal Doxorubicin To Treat AIDS Kaposi'S Sarcoma
    Comparison Study Of Liposomal Doxorubicin To Treat AIDS Kaposi'S SarcomaNational Center For Research Resources
    1999 - 2001
  • Phase II Study Of Autologous CD4  Zeta Gene Modified T Cells In HIV
    Phase II Study Of Autologous CD4 Zeta Gene Modified T Cells In HIVNational Center For Research Resources
    1999 - 2001
  • Autologous CD4 Zeta Gene Modified T Cells In HIV Infected Patients
    Autologous CD4 Zeta Gene Modified T Cells In HIV Infected PatientsNational Center For Research Resources
    1999 - 2001
  • Phase III Study Of Indinavir (IDV) With Zidovudine (ZDV) And Lamivudine (3TC)
    Phase III Study Of Indinavir (IDV) With Zidovudine (ZDV) And Lamivudine (3TC)National Center For Research Resources
    1998 - 1999
  • Phase II Study Of Intermittent Recombinant Human Interleukin-2 By Intravenously
    Phase II Study Of Intermittent Recombinant Human Interleukin-2 By IntravenouslyNational Center For Research Resources
    1998 - 2001
  • Phase II Study Of The Activity And Safety Of Autologus Cd4-Zeta Gene-Modified
    Phase II Study Of The Activity And Safety Of Autologus Cd4-Zeta Gene-ModifiedNational Center For Research Resources
    1998 - 2001
  • Comparison Study Of Liposomal Doxorubicin With/Without Bleomycin And Vincristine
    Comparison Study Of Liposomal Doxorubicin With/Without Bleomycin And VincristineNational Center For Research Resources
    1998 - 1998
  • Phase I Trial Of CD34+ Stem Cells Transduced With An HIV Ribozyme
    Phase I Trial Of CD34+ Stem Cells Transduced With An HIV RibozymeNational Center For Research Resources
    1998 - 2001
  • Phase II Study Of Indinavir (IDV) With Zidovudine (ZDV) And Lamivudine (3TC)
    Phase II Study Of Indinavir (IDV) With Zidovudine (ZDV) And Lamivudine (3TC)National Center For Research Resources
    1997 - 1997
  • Pharmacology Agenda
    Pharmacology AgendaNational Institute Of Allergy And Infectious Diseases
    1996 - 1999
  • Combination Vincristine And DDI In AIDS Related Kaposi'S Sarcoma
    Combination Vincristine And DDI In AIDS Related Kaposi'S SarcomaNational Center For Research Resources
    1996 - 1997
  • Neurology Agenda
    Neurology AgendaNational Institute Of Allergy And Infectious Diseases
    1996 - 1999
  • Immunology And Immune Based Therapy Agenda
    Immunology And Immune Based Therapy AgendaNational Institute Of Allergy And Infectious Diseases
    1996 - 1999
  • HIV Disease Research Agenda
    HIV Disease Research AgendaNational Institute Of Allergy And Infectious Diseases
    1996 - 1999
  • Core--Advanced Technology Laboratories
    Core--Advanced Technology LaboratoriesNational Institute Of Allergy And Infectious Diseases
    1996 - 1999
  • Complications Of HIV Disease Agenda
    Complications Of HIV Disease AgendaNational Institute Of Allergy And Infectious Diseases
    1996 - 1999
  • Study Of Continuous Infusion Or Subcutaneously Administered Proleukin
    Study Of Continuous Infusion Or Subcutaneously Administered ProleukinNational Center For Research Resources
    1996 - 1999
  • Outreach Agenda
    Outreach AgendaNational Institute Of Allergy And Infectious Diseases
    1996 - 1999
  • Open, Non-Comparative Phase II Study Of Topotecan As A Continuous Dose
    Open, Non-Comparative Phase II Study Of Topotecan As A Continuous DoseNational Center For Research Resources
    1996 - 1997
  • Outcomes Committee Agenda
    Outcomes Committee AgendaNational Institute Of Allergy And Infectious Diseases
    1996 - 1999
  • Women'S Health Agenda
    Women'S Health AgendaNational Institute Of Allergy And Infectious Diseases
    1996 - 1999
  • Continuous Infusion Proleukin (ALDESLEUKIN) Chiron Recombinant Interleukin
    Continuous Infusion Proleukin (ALDESLEUKIN) Chiron Recombinant InterleukinNational Center For Research Resources
    1995 - 1999
  • HIV-1 Derived Immunogens In Infected Individuals With >500 CD4 Cells/Cubic MM
    HIV-1 Derived Immunogens In Infected Individuals With >500 CD4 Cells/Cubic MMNational Center For Research Resources
    1995 - 1997
  • Comparison Of Safety And Activity Of HIV-1 Vaccine With Placebo
    Comparison Of Safety And Activity Of HIV-1 Vaccine With PlaceboNational Center For Research Resources
    1995 - 1997
  • Combination Vincristine And DDI Or DDC In AIDS Related Kaposi'S Sarcoma
    Combination Vincristine And DDI Or DDC In AIDS Related Kaposi'S SarcomaNational Center For Research Resources
    1995 - 1995
  • AIDS Associated Malignancies Clinical Trials Consortium
    AIDS Associated Malignancies Clinical Trials ConsortiumNational Cancer Institute
    1995 - 1997
  • Study Of MN Rgp120/Hiv-1 In HIV Infected Patients With 50-500 C4 Cells/Cubic MM
    Study Of MN Rgp120/Hiv-1 In HIV Infected Patients With 50-500 C4 Cells/Cubic MMNational Center For Research Resources
    1995 - 1996
  • Monotherapy VS Combination Therapy With Nucleoside Analogs In HIV Patients
    Monotherapy VS Combination Therapy With Nucleoside Analogs In HIV PatientsNational Center For Research Resources
    1995 - 1996
  • Extended Immunization With MN Rgp120/Hiv-1 Vaccine
    Extended Immunization With MN Rgp120/Hiv-1 VaccineNational Center For Research Resources
    1995 - 1996
  • Dose Escalating Safety And Tolerance Study Of Scd4-Pe40 In HIV Patients
    Dose Escalating Safety And Tolerance Study Of Scd4-Pe40 In HIV PatientsNational Center For Research Resources
    1995 - 1996
  • Phase II Study Of CD8+ T Cells Infused With Recombinant Interleukin-2
    Phase II Study Of CD8+ T Cells Infused With Recombinant Interleukin-2National Center For Research Resources
    1995 - 1995
  • Safety And Efficacy Of Zidovudine For Asymptomatic HIV Infected People
    Safety And Efficacy Of Zidovudine For Asymptomatic HIV Infected PeopleNational Center For Research Resources
    1995 - 1995
  • AIDS Clinical Trials Unit
    AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases
    1994 - 2003
  • Adult AIDS Clinical Research
    Adult AIDS Clinical ResearchNational Institute Of Allergy And Infectious Diseases
    1994 - 1995
  • Adult AIDS Clinical Trials Unit
    Adult AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases
    1992 - 1993
  • AIDS Institutional Training
    AIDS Institutional TrainingNational Institute Of Allergy And Infectious Diseases
    1990 - 1992
  • AIDS Clinical Trials Group Conversion From Ateu
    AIDS Clinical Trials Group Conversion From AteuNational Institute Of Allergy And Infectious Diseases
    1990 - 1991
  • Physician-Investigator Development Award Program
    Physician-Investigator Development Award ProgramNational Cancer Institute
    1985 - 1986
  • Prevention Of Graft-Vs-Host Disease
    Prevention Of Graft-Vs-Host DiseaseNational Cancer Institute
    1985 - 1985

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
  • Aetna HMO
  • BCBS Blue Card PPO
  • BCBS California CaliforniaCare HMO
  • BCBS California PPO
  • BCBS Texas BlueChoice
  • CIGNA HMO
  • CIGNA Open Access
  • CIGNA PPO
  • First Health PPO
  • Great West PPO
  • Health Net California Large Group PPO
  • Health Net HMO - Employer Group
  • Humana ChoiceCare Network PPO
  • Multiplan PHCS PPO
  • Multiplan PHCS PPO - Kaiser
  • Multiplan PPO
  • Pacificare HMO
  • United Healthcare - Direct Choice Plus POS
  • United Healthcare - Direct Options PPO

Physicians, view Dr. Mitsuyasu's full Doximity profile to:

  • Trade HIPAA-secure messages
  • Send and receive online faxes
  • Refer a patient
  • See their complete CV